Statistics

Total Visits

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab86

Select a period of time:

Number of views in the range

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab23

Views

Views
November 20252
December 20252
January 20260
February 20260
March 20265
April 20263
May 202611
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States12
Turkey2
United Kingdom2
Finland1
France1
Mexico1
Netherlands1
Romania1
Singapore1
South Africa1
 

Top cities views

Views
Santa Clara2
Memphis2
Ankara1
Ashburn1
Aubervilliers1
Centurion1
Crawley1
Cuauhtémoc1
Groningen1
Helsinki1